Improving Diabetes Research: Moving Beyond Animal Models. Charu Chandrasekera, Ph.D. Anne Bunner, Ph.D.

Similar documents
You are what you eat, or are you? The challenges of translating high-fat-fed rodents to human obesity and diabetes

FRIDAY, JUNE 21. Epidemiology/ Genetics. Symposium The Big Picture Genetic Architecture of Diabetes Room S 103 B

The Mediterranean Diet: HOW and WHY It Works So Well for T2DM

Glucose Homeostasis. Liver. Glucose. Muscle, Fat. Pancreatic Islet. Glucose utilization. Glucose production, storage Insulin Glucagon

Definition of diabetes mellitus

Discussion & Conclusion

Therapeutic strategy to reduce Glucagon secretion

NIH Public Access Author Manuscript Diabetologia. Author manuscript; available in PMC 2014 February 01.

Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs

History of Investigation

Inflammation & Type 2 Diabetes Prof. Marc Y. Donath

Personalized therapeutics in diabetes

GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration

Chief of Endocrinology East Orange General Hospital

Pathogenesis of Diabetes Mellitus

Industrialized Food Components and Obesity Risk. Kylie Kavanagh, VMS MS MPH Department of Pathology

BIOL212 Biochemistry of Disease. Metabolic Disorders - Obesity

Diabetes: What is the scope of the problem?

Treating Type 2 Diabetes with Bariatric Surgery. Goal of Treating T2DM. Remission of T2DM with Bariatric

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes

My Journey in Endocrinology. Samuel Cataland M.D

A Central Role of MG53 in Metabolic Syndrome. and Type-2 Diabetes

DEVELOPMENT OF NEW ANIMAL MODELS FOR TYPE 2 DIABETES MELLITUS AND PHARMACOLOGICAL SCREENING

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

Rhonda Eustice, PharmD, CDE. Will Power lasts about two weeks and is soluble in alcohol. Mark Twain

The uses of animal models in the evaluation of functional foods

New therapeutic targets for T2DM

Diabetes in Chronic Pancreatitis: When is it type 3c? Melena Bellin, MD Associate Professor, Pediatrics & Surgery Schulze Diabetes Institute

Endo 2 SLO Practice (online) Page 1 of 7

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010

Type 2 Diabetes and Cancer: Is there a link?

Animal Models of Diabetes and Insulin Resistance. Masakazu Shiota, D.V.M., Ph.D An Organ System.. Course. July 18, 2012

Lipids Carbohydrate Protein. Fatty Acids Glycerol. Mono/di-saccarides. Aminoacids. Fat Liver Muscle. Triglycerides Glycogen Protein

a. What is the stimulus? Consuming a large pumpkin spice muffin and caramel macchiato.

Subject Index. postprandial glycemia and suppression in serum 51 recommendations 119, 120 supplementation pros and cons 118, 119

associated with serious complications, but reduce occurrences with preventive measures

Type 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM

Spontaneously Diabetic Torii Lepr fa (SDT Fatty) Rat: A Novel Model of Obese Type 2 Diabetes

Obesity in aging: Hormonal contribution

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

NASH Bench to Bedside

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes

ROLE OF TASTE IN METABOLIC CONTROL OF TYPE 1 DIABETES MELLITUS

28/04/51. Introduction. Insulin signaling effects on memory and mood. Is accelerated brain aging a consequence of diabetes? chronic hyperglycemia

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function

Overview. o Limitations o Normal regulation of blood glucose o Definition o Symptoms o Clinical forms o Pathophysiology o Treatment.

IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013

Body Mass Index Chart = overweight; = obese; >40= extreme obesity

Atypical and Ketosis Prone Diabetes. Ashok Balasubramanyam, MD Baylor College of Medicine Houston, Texas

Obese Type 2 Diabetic Model. Rat Model with Early Onset of Diabetic Complications. SDT fatty rats. SDT fatty rats

Week 3, Lecture 5a. Pathophysiology of Diabetes. Simin Liu, MD, ScD

Scope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors

Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),

Diabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:

SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION

The Many Faces of T2DM in Long-term Care Facilities

Diabetes Pathophysiology and Treatment Strategies

The enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans

Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol

Yiying Zhang, PhD Research Scientist. Research Summary:

MBB317. Dr D MANGNALL OBESITY. Lecture 2

Helpful Hints for Taking Care of Your Diabetes. Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center

Polycomb protein Ezh2 regulates pancreatic β-cell Ink4a/Arf expression and regeneration in streptozotocin-induced diabetes mellitus

Drug Class Review Newer Diabetes Medications and Combinations

Control of Glucose Metabolism

GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.

la prise en charge du diabète de

R. Leibel Naomi Berrie Diabetes Center 19 March 2010

Dipeptidyl peptidase 4 inhibitor linagliptin can decrease the dosage of erythropoiesisstimulating

Metabolic and Cardiovascular Disease Models and Services MODELS AND SERVICES DESIGNED TO TAKE YOUR STUDY FURTHER

Individualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD

Metabolic Syndrome. DOPE amines COGS 163

SUPPLEMENTARY INFORMATION

What systems are involved in homeostatic regulation (give an example)?

Targeting simultaneously GLP-1, GIP and glucagon receptors : a new paradigm for treating obesity and diabetes

Importance of Nutrition

Journal Club WS 2012/13 Stefanie Nickl

효과적인경구혈당강하제의조합은? 대한당뇨병학회제 17 차연수강좌 ( ) 가천의대길병원내분비대사내과

DIABETES RESEARCH A CLINICIAN S OVERVIEW

Workshop. Factors influencing food intake? How decrease food choice related morbidity/mortality

Insulin resistance and pancreatic b cell failure

Eat Healthy. Learn How to Read Food Labels

New Paradigms of Type 2 Diabetes. From:

The Atoms of Life. What are other elements would you expect to be on this list? Carbon Hydrogen Nitrogen Oxygen Phosphorous Sulfur (sometimes)

ΦΛΕΓΜΟΝΗ ΚΑΙ ΔΙΑΒΗΤΗΣ

MOA: Long acting glucagon-like peptide 1 receptor agonist

BIOM2010 (till mid sem) Endocrinology. e.g. anterior pituitary gland, thyroid, adrenal. Pineal Heart GI Female

Wayne Gravois, MD August 6, 2017

Metabolism of medium and long chain triglycerides Role on energy balance. Hormone/Food intake pilot data

Newer Drugs in the Management of Type 2 Diabetes Mellitus

Gut hormones KHATTAB

Despite vigorous research aimed at combating type

Taking Translation into the Clinic: Can We Improve the Probability of Success?

FOR REVIEW. BMB Reports - Manuscript Submission. Manuscript Draft. Manuscript Number: BMB

Unmasking the evidence of efficacy and safety. Cheaper or Better DEBATE (pros) Panagiotis Halvatsiotis

What s New in Diabetes Treatment. Disclosures

HOW TO DEFINE GOOD BIOMARKERS OF HEALTH? Suzan Wopereis

EB Education Revision Guide. How to work with Homeostasis: Part 2 Blood Glucose Regulation

Transcription:

Improving Diabetes Research: Moving Beyond Animal Models Charu Chandrasekera, Ph.D. Anne Bunner, Ph.D. July 19, 2014

From Bench-to-Bedside Sulfonylurea Biguanide Dipeptidyl peptidase-4 inhibitor Glucagon-like peptide-1 receptor agonist

From Bench-to-Bedside Januvia DPP- 4 GLP-1 Victoza GLP-1 PI3K Akt Rap Erk1/2 Glyburide Insulin Secretion Pancreatic β-cell

Type 2 Diabetes Research 1. Animal models of human type 2 diabetes 2. Limitations of animal models 3. Humanizing type 2 diabetes research

1. Animal Models of Type 2 Diabetes in Basic Research

Animal Models of Diabetes

Deciphering Diabetes The Problem Research Questions: - How? - What? - Why? - Why not? - When? The Solution! - Where? - What else?

Rodent Models this is how we do it

Rodent Models: Surgical Induction Non-obese diabetic model Partial (10 90%) or Complete pancreatectomy Extent of pancreatectomy governs severity of disease

Rodent Models: Chemical Induction Streptozotocin Glucose GLUT2 Irreversible β-cell cytotoxicity Non-obese model Dosage governs severity of disease Alloxan

Rodent Models: Dietary Modification Cafeteria Diet

Rodent Models: Dietary Modification Pre-Defined High-Fat Diets 30% 20% Fat content 50% 40% 70% 60% Fat types Olive oil Butter Coconut oil Fish oil Lard Beef tallow Vegetable shortening Obese diabetic models Diet type influences disease phenotype Other Components High Sucrose High Fructose Protein Micronutrients

Rodent Models: Genetic Models Obese diabetic models Naturally occurring Spontaneous Genetic Models Leptin and leptin receptor mutations e.g., ob/ob mouse, db/db mouse, Zucker fatty rat, Zucker diabetic fatty rat

Rodent Models: Genetic Models Knock-out Genetically Engineered Models Obese & non-obese Disease severity depends on genetic alteration Knock-in Transgenic

Rodent Models of Diabetes > 50 publications / month Chandrasekera et al. ALTEX 2014; 31:157-76. ob/ob db/db ZDF Other Rats Spontaneously Chemical Transgenic Diabetic Dietary Surgical

2. Limitations of Animal Models

Deciphering Diabetes In order for a rodent model to have relevance to human diabetes, it should display causes natural history pathophysiology manifestations complications drug responses in a manner similar to what is observed in humans.

Deciphering Diabetes Human T2DM = multifactorial & complex Type 2 Diabetes

Of Rodents and Men 1. Experimental Limitations 2. Biological Limitations 3. Species Differences

1. Experimental Limitations: Surgical Induction Sudden pancreatic loss Extent governs disease severity e.g., 80% resection gives mild hyperglycemia β-cell regeneration & full recovery Loss of counter-regulation e.g., glucagon Chandrasekera et al. ALTEX 2014; 31:157-76

1. Experimental Limitations: Chemical Induction Dosage dependence Streptozotocin Extrapancreatic cytotoxic effects e.g., disruption of the HPG axis Human β-cells resistant to streptozotocin in rodents, enter cells via GLUT2 GLUT1 GLUT3 Chandrasekera et al. ALTEX 2014; 31:157-76

1. Experimental Limitations: Dietary Induction Diet type Diet components Control diet Age of onset of diet Duration of diet Lai et al. Nutr Diabetes, 2014

1. Experimental Limitations: Genetic Induction Leptin mutations rare in humans Wang et al. Curr Diab Rev. 2014; 10:131-45 Single-gene effect Exaggerated & compensatory effects Developmental defects Bunner et al. World J Diab. 2014; 5:146-159

2. Biological Limitations Age young adult old Sex No disease phenotype Prominent disease phenotype Strain C57BL/6J, AKR/J, FVB/N, 129SeVe

2. Biological Limitations Heterogeneity among strains 60% weight gain Heterogeneity within one strain 30% weight gain 10% weight gain Control High Fat Diet Weight gain Plasma glucose Plasma insulin Serum lipid Glucose tolerance

2. Biological Limitations Health of laboratory animals is poor by human standards Control laboratory rodents are metabolically morbid: why it matters Obese Insulin resistant Hypertesive On a trajectory to premature death profound differences in experimental outcome confound data interpretation and outcomes of human studies Martin et al. PNAS 2010; 107:6127-33

Chandrasekera et al. ALTEX 2014; 31:157-76 3. Species Differences

3. Species Differences

3. Species Differences α δ β

3. Species Differences

Critiques of Rodent Models Of rodents and men: species specificity of glucose regulation and type 2 diabetes research. Chandrasekera et al. ALTEX 2014; 31(2):157-76. Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes. Wang et al. Curr Diab Rev. 2014; 10(2):131-45. Knockout mouse models of insuling signaling: relevance past and future. Bunner et al. World J Diabetes. 2014; 5(2):146-159. You are what you eat, or are you? The challenges of translating high-fatfed rodents to human obesity and type 2 diabetes. Lai et al. Accepted for publication in Nutrition & Diabetes, 2014 From animal models to clinical practicality: lessons learned from current translational progress of diabetic peripheral neuropathy. Li et al. In: Souayah N, ed. Peripheral Neuropathy - A New Insight into the Mechanism, Evaluation and Management of a Complex Disorder. New York, NY 2013.

Limitations of Rodent Models: The Case of ZnT8 Zn 2+ insulin secretory granules ZnT8 zinc transporter Genetic study in a small French population identified novel risk loci for T2D: Sladek et al. Nature 2007; 445:881-5. insulin secretory granules

Limitations of Rodent Models: The Case of ZnT8 ZnT8 zinc transporter ZnT8 Gene Deletion ZnT8 Knockout

Limitations of Rodent Models: The Case of ZnT8

Limitations of Rodent Models: The Case of ZnT8 ZnT8 Knockout Variability Age Sex Strain Weight gain Blood glucose Plasma insulin Glucose tolerance Insulin secretion Diet Disease Severity No Change Significant Increase Marked Reduction

Limitations of Rodent Models: The Case of ZnT8 Pound et al. PLoS One 2012; 7:e40972

Limitations of Rodent Models: The Case of ZnT8 intriguing differences between the phenotypes of the animal models 150,000 humans with protein-truncating mutations loss of ZnT8 increased disease risk loss of ZnT8 reduced disease risk Rutter GA. Islets 2010; 2:49-50. Flannnick et al. Nat Genet 2014; 46:357-63.

Limitations of Rodent Models causes natural history pathophysiology manifestations complications drug responses

Deciphering Diabetes NOT The Solution! The Problem

3. Human-based Methods

Human Data Modeling complex interactions in silico Algorithms for pancreas function were used to develop a closedloop insulin pump. Kovatchev B, et al. (2009) J Diabetes Sci Technol 3, 44 55. Kovatchev B, et al. (2010) J Diabetes Sci Technol 4, 1374 1381.

Genome-Wide Association Studies Patients Nonpatients Disease-specific markers Patient DNA Compare differences to discover genetic markers associated with diseases Non-patient DNA Non-disease markers

Human Populations Population-based studies reveal genetic and environmental factors.

Odds Ratio Dietary factors AHS-2 study 41,000 people asked about diets and health Followed for 2 years 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 Diabetes Incidence * * * * 95% CI shown Tonstad S, et al. (2013) Nutr Metab Cardiovasc Dis 23, 292-9.

Human Beings Safe and ethical PET and functional MRI can be used to monitor glucose and insulin in volunteers. Bertoldo A, et al. (2006) Diabetes 55, 3028-3037. Tesfaye and Selvarajah (2012) Diab/Metab Res Rev 28, S8-S14. Kullmann, et al. (2012) Human Brain Mapping 33, 1052 1061

GLP-1 and insulin secretion Glucagon-like peptide 1 (GLP-1) is a peptide important for normal glucose tolerance Victoza is a GLP-1 agonist Does GLP-1 work the same way in diabetes patients as in healthy volunteers? Drug that temporarily blocks GLP-1 activity drug Healthy volunteers drug Type 2 Diabetes patients GLP-1 GLP-1 Insulin secretion Insulin secretion Salehi M, et al. (2010) Diabetes 59, 1330-1337.

Human Organs Microfluidic systems mimic architecture of tissues and organs Commercially available liver cells http://www.medicyte.com/products/human-upcyte-hepatocytes.html http://kirkstall.org/index.php/quasi-vivo-system/

Human Tissues Tissues from: cadavers surgical patients

Human islets for drug screening Cultured human islets from cadavers Islets produced insulin in response to glucose Islets exposed to 1,280 compounds Used automated technology to detect changes in insulin secretion Functional cultured islets indicated by white arrowheads Walpita D, et al. (2012) J Biomol Screen 17, 509-518.

Human islets for drug screening Functional cultured islets indicated by white arrowheads Walpita D, et al. (2012) J Biomol Screen 17, 509-518.

Human Cells A human pancreatic β- cell line is now available for insulin secretion studies. Ravassard P, et al. (2011) J Clin Invest 121, 3589-3597.

Inflammation and insulin resistance in human skeletal muscle How does inflammation contribute to insulin resistance? What genes are involved? Researchers used muscle cells from volunteers Turned off a certain gene in some samples to observe differences in response Stimulus Signaling protein Austin RL, et al. (2008) Diabetes 57, 2066-73. Insulin resistance Bouzakri K and Zierath JR (2007) J Biol Chem 282, 7783-7789.

Many options for human studies Human studies are: Reliable Relevant Practical

Thank you for your attention! Questions?